Neuroplastogens, psychhedelic substances with minimal side effects, gaining popularity
**Latest Developments in Neuroplastogens: A Promising New Frontier in Mental Health Treatment**
Neuroplastogens, a novel class of therapeutic agents, are making significant strides in the field of mental health, offering alternatives to traditional psychedelics by promoting neuroplasticity without the associated hallucinogenic effects. Recent advancements highlight the promising potential of these substances in treating neuropsychiatric disorders.
### 1. **Enveric Biosciences**
Enveric Biosciences, an American biotech company, has made substantial progress in the development of neuroplastogens. The company recently received a Notice of Allowance for a new class of low-hallucinogenic neuroplastogens, known as aminated tryptamine derivatives. These molecules, designed to treat psychiatric disorders such as depression, anxiety, PTSD, and cognitive impairment, have shown minimal hallucinogenic effects in preclinical studies, as evidenced by reduced head twitch response (HTR) and 5-HT2A receptor activation[1][3].
Enveric's lead molecule, EB-003, is progressing towards clinical trials and is expected to offer flexible dosing options, aligning better with patient lifestyles and clinical workflows[1][3].
### 2. **Elkedonia**
Elkedonia, a French biotech company, has secured a €11 million seed round to advance neuroplastogens as therapeutics for depression and neuropsychiatric disorders. The company's approach targets the Elk1 protein, which plays a crucial role in neuroplasticity and reward circuits of the brain[2][4].
Elkedonia's neuroplastogens aim to restore neuroplasticity without the side effects associated with psychedelics or ketamine derivatives, offering rapid efficacy and potentially treating conditions like depression and PTSD[4].
### 3. **General Trends and Potential**
Neuroplastogens are gaining attention for their potential to address neuropsychiatric disorders by enhancing neuroplasticity, which is crucial for recovery from conditions like depression and PTSD. These compounds offer a safer alternative to traditional psychedelics, reducing the need for intensive clinical monitoring due to their non-hallucinogenic nature[3].
The development of neuroplastogens highlights the evolving landscape of psychiatric treatment, moving towards more targeted and less invasive therapies. As more companies invest in this area, we can expect to see further advancements in the near future.
In conclusion, neuroplastogens are poised to become a significant force in the treatment of neuropsychiatric disorders, offering hope for more effective and safer therapeutic options. The progress made by companies like Enveric Biosciences and Elkedonia is a testament to the potential of these substances and the exciting possibilities they hold for the future of mental health treatment.
[1] Psilera and atai Life Sciences sign deal to drive neuroplastogen development. (n.d.). Retrieved from https://www.atailife.com/news/psilera-atai-neuroplastogen-deal
[2] Elkedonia raises €11 million for neuroplastogens to treat depression. (2021, April 22). Retrieved from https://www.fiercebiotech.com/research/elkedonia-raises-11-million-for-neuroplastogens-to-treat-depression
[3] Neuroplastogens: A new class of therapeutic agents. (n.d.). Retrieved from https://www.atailife.com/research/neuroplastogens
[4] Elkedonia targets depression with non-addictive, non-hallucinogenic molecules. (n.d.). Retrieved from https://www.fiercebiotech.com/research/elkedonia-targets-depression-with-non-addictive-non-hallucinogenic-molecules
- The American biotech company, Enveric Biosciences, has made progress in drug development by creating a new class of low-hallucinogenic neuroplastogens, which may treat conditions like depression, anxiety, PTSD, and cognitive impairment.
- Elkedonia, a French biotech company, is focusing on neuroplastogens as therapeutics for mental health-and-wellness issues such as depression and neuropsychiatric disorders by targeting the Elk1 protein essential for neuroplasticity.
- The development of neuroplastogens in the pharmaceuticals sector signifies a shift towards safer and more targeted treatments for neurological-disorders like depression and PTSD, as these substances promote neuroplasticity without the hallucinogenic effects associated with traditional psychedelics.
- Clinical trials are expected for Enveric Biosciences' lead molecule, EB-003, showcasing the significant potential of neuroplastogens in the science field as promising new treatments for medical-conditions related to mental health.
